Audience -All Patients & Families-Adults & Aging-Chapters-Donors & Supporters-Healthcare Providers-Kids & Young Adults-Men-Payers-Spanish Speaking Individuals-Undiagnosed-Women & Girls Type of Bleeding Disorder -All Bleeding Disorders-Hemophilia-Inhibitors-Rare Bleeding Disorders-Von Willebrand Disease Topic -Advocacy-Awareness-Blood & Product Safety-Bone & Joint Health-Community-COVID-19-Digital Health-Diversity, Equity & Inclusion-Fitness & Nutrition-Future Therapies-Health Equity-Healthcare Insurance-HIV & Hepatitis C-Mental Health-Pain Management-Sexual & Reproductive Health-Research-Treatment & Care 10 Dec Hemophilia A, Pregnancy, and Inhibitors: Where We’ve Been and Where We Are Going Dec 10, 2025 05 Nov Who Is Left Out of Bleeding Disorders Care? Addressing Health Equity Nov 5, 2025 24 Sep Bleeding Disorders Research Collaborative Update Sep 24, 2025 13 Aug HLA Alleles Associated with Inhibitor Development in Severe Hemophilia A Aug 13, 2025 16 Jul Research in Children and Adolescents with Inherited Bleeding Disorders Jul 16, 2025 28 May A New Era in Menstrual Care: The Revolutionary Science of Wearable Neurostimulation May 28, 2025 01 Jun Immune tolerance induction in the era of emicizumab - still the first choice for patients with hemophilia A and inhibitors Jun 1, 2022 - Jun 1, 2022 18 May Implementation Science May 18, 2022 - May 18, 2022 16 Mar Breakthrough Bleeding Episodes in Pediatric Severe Hemophilia a Patients with and without Inhibitors Receiving Emicizumab Prophylaxis: a Single-center Retrospective Review Mar 16, 2022 09 Jun Danger Signals and Inhibitor Development Jun 9, 2021 - Jun 9, 2021 29 May Town Hall Webinar - Inhibitors: Coping During COVID-19 May 29, 2020
28 May A New Era in Menstrual Care: The Revolutionary Science of Wearable Neurostimulation May 28, 2025
01 Jun Immune tolerance induction in the era of emicizumab - still the first choice for patients with hemophilia A and inhibitors Jun 1, 2022 - Jun 1, 2022
16 Mar Breakthrough Bleeding Episodes in Pediatric Severe Hemophilia a Patients with and without Inhibitors Receiving Emicizumab Prophylaxis: a Single-center Retrospective Review Mar 16, 2022
